Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 339 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Thiazolidinedione Clear all
Terminated Phase 2 Interventional Results available

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

NCT00612066
View directory record Official record
Conditions
Cushing's Disease
Interventions
rosiglitazone maleate
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 11, 2026, 4:08 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

NCT06657209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
Interventions
Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone
Procedure · Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

NCT01100619
View directory record Official record
Conditions
Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma
Interventions
rosiglitazone, XL184
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Rosiglitazone Effect on Mitochondria and Lipoatrophy

NCT00367744
View directory record Official record
Conditions
HIV Infections
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

The Impact of Obesity and Obesity Treatments on Breast Cancer

NCT00933309
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Avandamet
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients

NCT00123643
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rosiglitazone, glyburide
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
25 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects

NCT00615212
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK376501, Midazolam, Rosiglitazone, Flurbiprofen
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Use of Rosiglitazone to Treat Asthma

NCT00614874
View directory record Official record
Conditions
Asthma
Interventions
rosiglitazone
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock

NCT01352182
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Pioglitazone hydrochloride
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Endothelial Dysfunction as a Risk Factor in HIV Study

NCT00039663
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin, Gemfibrozil, Rosiglitazone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 3 Interventional

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

NCT00598793
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, insulin glargine, metformin, pioglitazone
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Concord, California • Los Angeles, California • Walnut Creek, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gene Regulation by Thiazolidinediones

NCT00567593
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Rosiglitazone
Drug
Lead sponsor
James Lewis
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia

NCT00006493
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
Rosiglitazone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

NCT02730377
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylurea, thiazolidinediones
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
179
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tuscumbia, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 4 Interventional

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

NCT00672919
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

NCT00753896
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Mesa, Arizona • Tempe, Arizona • Concord, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Preferred Treatment of Type 1.5 Diabetes

NCT00194896
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rosiglitazone, glyburide
Drug
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 69 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

NCT00789750
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Colesevelam, Placebo, Pioglitazone
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
141
States / cities
Birmingham, Alabama • Montgomery, Alabama • Green Valley, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 4 Interventional

The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle

NCT01799850
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Pioglitazone, placebo
Drug
Lead sponsor
East Tennessee State University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 11, 2026, 4:08 AM EDT
Terminated Phase 3 Interventional

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

NCT00376181
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone and Azilsartan, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
59
States / cities
Huntsville, Alabama • Tallassee, Alabama • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome

NCT00656851
View directory record Official record
Conditions
HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy, The Metabolic Syndrome
Interventions
Pioglitazone, Exercise Training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
28 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 11, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

NCT00381238
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Sun City, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 11, 2026, 4:08 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

NCT01931566
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Pioglitazone placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years to 83 Years
Enrollment
3,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
34
States / cities
Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 11, 2026, 4:08 AM EDT
Terminated Not applicable Interventional

Rosiglitazone-Induced Weight Gain

NCT00225225
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rosiglitazone, dietary recommendation for weight maintenance
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Oct 11, 2026, 4:08 AM EDT